+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05886036

Randomized Phase 2 Trial Comparing Mosunetuzumab and Rituximab Treatments for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Led by National Cancer Institute (NCI) · Updated on 2026-10-14

70

Participants Needed

37

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are comparing two immunotherapy drugs, mosunetuzumab and rituximab, to see which is better at improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma NLPHL. This Phase II trial studies these monoclonal antibodies that target the CD20 protein on B cells and some cancer cells, potentially helping the immune system fight the cancer. The study also aims to understand the effects on tumor and immune responses, identify biomarkers, and explore safety and activity of these treatments. Participants are randomly assigned to one of two groups. One group receives mosunetuzumab as a subcutaneous injection on specific days of a 21-day cycle, for up to 8 cycles unless the disease progresses or side effects occur. The other group receives rituximab intravenously and subcutaneously over 28-day cycles, for up to 2 cycles spaced 8 weeks apart. Patients who experience disease progression may switch to the other treatment at week 12. Both groups undergo PETCT scans at baseline and end of treatment, bone marrow and tissue biopsies, and blood sample collection throughout the trial. During the study, participants have biopsies and imaging tests to monitor their disease and immune status. Blood samples are collected regularly to evaluate molecular responses. Researchers measure progression-free survival, tumor response, duration of response, and overall survival over up to two years. After completing treatment, participants are followed every six months for two years to observe long-term outcomes. The study also monitors safety and collects data to better understand how these treatments affect the tumor environment.

CONDITIONS

Brief Title

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here